CytomX Stock: Additional Run Up Into The Q1'26 Readout Is Possible (NASDAQ:CTMX)

Core Insights - CytomX Therapeutics is developing two biologics targeting various cancers, with one already showing promising phase 1 data and the other expected to release phase 1 data soon [1] Company Overview - CytomX Therapeutics is listed on NASDAQ under the ticker CTMX [1] - The company focuses on biopharmaceuticals with potential applications in oncology [1] Clinical Development - One of the biologics has produced compelling results in phase 1 trials, indicating potential efficacy [1] - The second biologic is anticipated to generate phase 1 data shortly, which could provide further insights into its therapeutic potential [1]